Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) fell 7.6% during trading on Tuesday. The stock traded as low as $19.88 and last traded at $19.7840. Approximately 1,246,354 shares were traded during mid-day trading, a decline of 71% from the average session volume of 4,276,905 shares. The stock had previously closed at $21.41.
Wall Street Analyst Weigh In
A number of research firms have commented on REPL. Wolfe Research upgraded Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Replimune Group in a research note on Wednesday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Replimune Group in a report on Monday, October 5th. Piper Sandler boosted their price objective on Replimune Group from $14.00 to $27.00 and gave the company an “overweight” rating in a report on Monday. Finally, Leerink Partners increased their target price on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Replimune Group presently has a consensus rating of “Moderate Buy” and an average target price of $18.17.
Get Our Latest Stock Analysis on REPL
Replimune Group Trading Down 8.0%
The firm has a market cap of $1.87 billion, a PE ratio of -7.06 and a beta of 0.93. The company has a current ratio of 7.11, a quick ratio of 6.90 and a debt-to-equity ratio of 0.59. The business has a fifty day moving average price of $14.89 and a 200 day moving average price of $10.11.
Replimune Group (NASDAQ:REPL – Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. Analysts forecast that Replimune Group, Inc. will post -2.40 EPS for the current year.
Insider Buying and Selling at Replimune Group
In other news, Director Joseph P. Slattery sold 5,200 shares of the business’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $21.80, for a total transaction of $113,360.00. Following the transaction, the director directly owned 1,467 shares in the company, valued at $31,980.60. The trade was a 78.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kapil Dhingra sold 21,500 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $19.00, for a total transaction of $408,500.00. Following the transaction, the director directly owned 21,669 shares of the company’s stock, valued at $411,711. This represents a 49.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 5.40% of the company’s stock.
Institutional Trading of Replimune Group
A number of institutional investors have recently bought and sold shares of REPL. Quantinno Capital Management LP boosted its stake in Replimune Group by 782.7% in the 1st quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock worth $830,000 after buying an additional 96,188 shares during the last quarter. Montanova Capital LLC increased its stake in shares of Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after acquiring an additional 168,000 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Replimune Group during the 1st quarter valued at about $921,000. Squarepoint Ops LLC purchased a new position in shares of Replimune Group during the 2nd quarter worth about $1,454,000. Finally, Deutsche Bank AG purchased a new position in shares of Replimune Group during the 2nd quarter worth about $857,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.
Replimune Group Company Profile
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
Further Reading
- Five stocks we like better than Replimune Group
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
